Grants and Contributions
About this information
In June 2016, as part of the Open Government Action Plan, the Treasury Board of Canada Secretariat (TBS) committed to increasing the transparency and usefulness of grants and contribution data and subsequently launched the Guidelines on the Reporting of Grants and Contributions Awards, effective April 1, 2018.
The rules and principles governing government grants and contributions are outlined in the Treasury Board Policy on Transfer Payments. Transfer payments are transfers of money, goods, services or assets made from an appropriation to individuals, organizations or other levels of government, without the federal government directly receiving goods or services in return, but which may require the recipient to provide a report or other information subsequent to receiving payment. These expenditures are reported in the Public Accounts of Canada. The major types of transfer payments are grants, contributions and \'other transfer payments\'.
Included in this category, but not to be reported under proactive disclosure of awards, are (1) transfers to other levels of government such as Equalization payments as well as Canada Health and Social Transfer payments. (2) Grants and contributions reallocated or otherwise redistributed by the recipient to third parties; and (3) information that would normally be withheld under the Access to Information Act and the Privacy Act.
$6,037,700.00
Jan 1, 2026
For-profit organization
515743
515743
Establish oligonucleotide manufacturing, and self-amplifying RNA (saRNA) manufacturing capabilities.
$498,000.00
May 1, 2025
For-profit organization
UK Biomanufacturing - 10140683 - H5Nx Vaccine - Pan-H5Nx subtype Influenza Protection: mRNA Vaccine Using optimized Lipid Nanoparticles
1032265
“As part of the international consortium project “H5Nx Vaccine: Pan-H5Nx subtype Influenza Protection: mRNA Vaccine Using optimized Lipid Nanoparticles”, this project proposes to develop a groundbreaking biomanufacturing platform for a novel pan-H5Nx mRNA vaccine.
$15,000,000.00
Aug 10, 2023
For-profit organization
819504
819504
This project is to build a Good Manufacturing Practices (GMP) facility to manufacture lipids, conduct lipid nanoparticle (LNP) formulation and expand the company's existing vaccine manufacturing capacity in Calgary, AB.
$5,000,000.00
Mar 3, 2023
For-profit organization
PC0006556
PC0006556
Establish contract manufacturing facility for vaccines and lipids in Western Canada
$7,000,000.00
Jul 28, 2022
For-profit organization
COVID-19 - A toolbox for the production of nucleic acid products for vaccines and therapeutics
1003190
The COVID-19 pandemic has impacted the global supply of nucleic acid products including mRNA and plasmid DNA and delivery vehicles such as lipid nanoparticles which have been demonstrated to be important tools for outbreak management predominately via a mass vaccination approach. The time to market for these products is hindered by complexities in production, production processes, analytical methods, and complicated supply chain, intellectual property landscape and quality management systems. Northern RNA's intention is to provide agile platform production approaches and enabling systems, infrastructure, and resources to ensure access to nucleic acid products and their formulations for researchers, organizations, and healthcare providers in managing the current pandemic and to heighten domestic and global preparedness for the future.
$30,000.00
Oct 1, 2021
For-profit organization
Youth- NorthernRNA - New Youth - Sept/21
979998
The firm is aiming to develop lab methodologies that are applicable for oligonucleotide separation and its purification. These methods will be applicable depending on the length of the oligonucleotide synthesized and degree of purity required for its final application. The Youth will support the method development in this regard.
$60,000.00
May 17, 2021
For-profit organization
Youth-NorthernRNA-New Grad support 21-21
973217
Northern RNA is developing GMP manufacturing of mRNA and DNA based vaccines at our Calgary, Alberta based facility. GMP certification requires the development and documentation of all processes related to the manufacturing of product. It is our goal to be manufacturing 100 million doses of vaccines by early Q1 2022. This project is to document our proprietary GMP manufacturing processes and support the writing of the required Standard Operating Procedures (SOPs). This project will allow us to accelerate our GMP certification process to ensure we meet our goal of supplying 100 million doses of vaccines to domestic clients.